Skip to main content
New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer
Published Web Location
https://journals.lww.com/co-obgyn/fulltext/2024/02000/new_approaches_for_human_epidermal_growth_factor.7.aspxNo data is associated with this publication.
Abstract
Purpose of review
In recent years, there has been a flurry of activity in the human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer space. New, powerful drugs like trastuzumab deruxtecan have challenged our fundamental definition of what HER2 expression means as a predictive biomarker.Recent findings
Recent approvals of multiple agents in the second line-metastatic setting have given patients access to a variety of new agents, but also raise questions with regard to optimal sequencing.Summary
This review will explore current issues with HER2 testing, recently approved drugs in the HER2+ and HER2 low spaces, as well as novel agents/combinations on the horizon.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.